<DOC>
	<DOC>NCT00755404</DOC>
	<brief_summary>The current study is initiated in order to assess the impact of a PD solution containing L-carnitine on insulin sensitivity evaluated by measuring insulin requirement.</brief_summary>
	<brief_title>Effect of an L-Carnitine-Containing Peritoneal Dialysis (PD) Solution on Insulin Sensitivity in Diabetic Patients on Continuous Ambulatory Peritoneal Dialysis (CAPD)</brief_title>
	<detailed_description />
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>1. Age ≥18 years 2. Have a diagnosis of ESRD and have been on Continuous Ambulatory Peritoneal Dialysis (CAPD) for at least 3 months 3. Have Type 2 Diabetes, diagnosed according to American Diabetes Association (fasting glucose ≥126 mg/dl and 2 h glucose at OGTT ≥200 mg/dl), and treated with multiple daily insulin injection or with HbA1c &gt; 8.5% (No oral antidiabetic) 4. Be in a stable clinical condition during the four weeks immediately prior to Screening Period as demonstrated by medical history, physical examination and laboratory testing 5. Have a blood hemoglobin concentration above 8,5 g/100ml (data will be verified with Investigators) 6. Have not experienced peritonitis episodes in the last 3 months 7. Be treated with Extraneal (nocturnal exchange bag solution) for at least 1 month 8. Be treated with 3 diurnal exchange bag solutions (solution bags with 1.5% or 2.5% glucose) and one nocturnal exchange bag solution (Extraneal) 9. Have Kt/V urea measurement &gt; 1.7 per week in a previous test performed within 3 months that should be confirmed at Baseline Visit 10. Have a minimum weekly creatinine clearance of 45 litres in a previous test performed within 6 months that should be confirmed at Baseline Visit 11. Have a D/P Creatinine ratio at Peritoneal Equilibration Test (PET) between 0.50 and 0.81 in a previous test performed within 6 months that should be confirmed at Baseline Visit 12. Have a D/P Glucose ratio at Peritoneal Equilibration Test (PET) between 0.26 and 0.49 in a previous test performed within 6 months that should be confirmed at Baseline Visit 13. Be treated by the participating clinical Investigator for a period of at least three months 14. Have understood and signed the Informed Consent Form. 1. Have a history of drug or alcohol abuse in the six months prior to entering the protocol 2. Type 2 Diabetic patients under oral antidiabetic treatment with HbA1C &lt; 8.5% 3. Be in treatment with androgens 4. Have clinically significant abnormal liver function test (SGOT, SGPT, and gammaGT &gt; 2 times the upper normal limit) 5. Have acute infectious conditions (i.e.: pulmonary infection, acute hepatitis, high or low urinary tract infections, renal parenchymal infection, pericarditis, etc) 6. Have a history of congestive heart failure and clinically significant arrhythmia 7. Have an history of epilepsy or any CNS disease 8. Have malignancy within the past 5 years, including lymphoproliferative disorders 9. Have any medical condition that, in the judgment of the Investigator, would jeopardize the patient's safety following exposure to study drug 10. Have a history of LCarnitine therapy or use in the month prior to entering the protocol 11. Have used any investigational drug in the 3 months prior to entering the protocol 12. Be in pregnancy, lactation, fertility age without protection against pregnancy by adequate contraceptive means</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Peritoneal dialysis</keyword>
	<keyword>L-carnitine</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Glucose homeostasis</keyword>
	<keyword>Dyslipidemia</keyword>
</DOC>